Forte Biosciences (FBRX) Current Assets (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Current Assets of $65.1 million for Q1 2026, up 38.07% year-over-year from $47.2 million in Q1 2025, and down 19.21% quarter-over-quarter from $80.6 million in Q4 2025.
Forte Biosciences (FBRX) Current Assets (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Current Assets for 11 consecutive years, with $65.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 38.07% year-over-year to $65.1 million; the TTM figure through Mar 2026 stood at $65.1 million (up 38.07% YoY), while the FY2025 annual figure was $80.6 million, up 31.37% from the prior year.
- Current Assets eased to $65.1 million in Q1 2026 per FBRX's latest filing, from $80.6 million in the prior quarter.
- Across five years, Current Assets topped out at $107.6 million in Q2 2025 and bottomed at $17.7 million in Q3 2024.
- Historically, Current Assets has averaged $50.0 million across 5 years, with a median of $41.5 million in 2022.
- Annual changes were most pronounced in 2024 — Current Assets sank 62.49% — and 2025, when it jumped 440.03%.
- Forte Biosciences' Current Assets stood at $41.5 million in 2022, then decreased by 7.67% to $38.3 million in 2023, then jumped by 60.06% to $61.3 million in 2024, then soared by 31.37% to $80.6 million in 2025, then retreated by 19.21% to $65.1 million in 2026.
- Business Quant data shows FBRX's Current Assets at $65.1 million in Q1 2026, $80.6 million in Q4 2025, and $95.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 203.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 203.10 Mn |
| Mar 31, 2026 | 65.11 Mn |
| Dec 31, 2025 | 80.59 Mn |
| Sep 30, 2025 | 95.41 Mn |
| Jun 30, 2025 | 107.62 Mn |
| Mar 31, 2025 | 47.16 Mn |
| Dec 31, 2024 | 61.35 Mn |
| Sep 30, 2024 | 17.67 Mn |
| Jun 30, 2024 | 25.71 Mn |
| Mar 31, 2024 | 31.50 Mn |
| Dec 31, 2023 | 38.33 Mn |
| Sep 30, 2023 | 47.10 Mn |
| Jun 30, 2023 | 30.75 Mn |
| Mar 31, 2023 | 36.27 Mn |
| Dec 31, 2022 | 41.51 Mn |
| Sep 30, 2022 | 44.59 Mn |
| Jun 30, 2022 | 38.85 Mn |
| Mar 31, 2022 | 40.41 Mn |
| Dec 31, 2021 | 42.52 Mn |
| Sep 30, 2021 | 46.56 Mn |